AR011178A1 - SODIUM SALT COMPOUND OF (ACID (E) 4,6-DICHLORO-3- (2-OXO-1- FENILPIRROLIDIN-3-ILIDENO-METHYL) -1H-INDOL-2-CARBOXILICO IN ITS HYDRATED FORM, PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND METHOD OF TREATMENT USING SUCH COMPOUND - Google Patents
SODIUM SALT COMPOUND OF (ACID (E) 4,6-DICHLORO-3- (2-OXO-1- FENILPIRROLIDIN-3-ILIDENO-METHYL) -1H-INDOL-2-CARBOXILICO IN ITS HYDRATED FORM, PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND METHOD OF TREATMENT USING SUCH COMPOUNDInfo
- Publication number
- AR011178A1 AR011178A1 ARP980100948A ARP980100948A AR011178A1 AR 011178 A1 AR011178 A1 AR 011178A1 AR P980100948 A ARP980100948 A AR P980100948A AR P980100948 A ARP980100948 A AR P980100948A AR 011178 A1 AR011178 A1 AR 011178A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- preparation
- treatment
- sodium salt
- ilideno
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
Una forma hidratada cristalina de la sal de sodio del compuesto de formula (I), los procesos para su preparacion y su uso en terapia. Dichoscompuestos son utiles para el tratamiento o prevencion de danos neurotoxicos y enfermedades degenerativas.A crystalline hydrated form of the sodium salt of the compound of formula (I), the processes for its preparation and its use in therapy. Said compounds are useful for the treatment or prevention of neurotoxic damage and degenerative diseases.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704498.6A GB9704498D0 (en) | 1997-03-05 | 1997-03-05 | Chemical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR011178A1 true AR011178A1 (en) | 2000-08-02 |
Family
ID=10808697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980100948A AR011178A1 (en) | 1997-03-05 | 1998-03-03 | SODIUM SALT COMPOUND OF (ACID (E) 4,6-DICHLORO-3- (2-OXO-1- FENILPIRROLIDIN-3-ILIDENO-METHYL) -1H-INDOL-2-CARBOXILICO IN ITS HYDRATED FORM, PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND METHOD OF TREATMENT USING SUCH COMPOUND |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0966463A1 (en) |
| JP (1) | JP2001513796A (en) |
| KR (1) | KR20000075907A (en) |
| CN (1) | CN1249750A (en) |
| AP (1) | AP9901637A0 (en) |
| AR (1) | AR011178A1 (en) |
| AU (1) | AU6825198A (en) |
| BG (1) | BG103779A (en) |
| BR (1) | BR9808305A (en) |
| CA (1) | CA2282851A1 (en) |
| CO (1) | CO4940415A1 (en) |
| EA (1) | EA199900710A1 (en) |
| EE (1) | EE9900387A (en) |
| GB (1) | GB9704498D0 (en) |
| HR (1) | HRP980114A2 (en) |
| HU (1) | HUP0002109A2 (en) |
| ID (1) | ID24207A (en) |
| IL (1) | IL131489A0 (en) |
| IS (1) | IS5166A (en) |
| NO (1) | NO994303L (en) |
| NZ (1) | NZ337315A (en) |
| OA (1) | OA11154A (en) |
| PE (1) | PE51399A1 (en) |
| PL (1) | PL335652A1 (en) |
| SK (1) | SK119699A3 (en) |
| TR (1) | TR199902117T2 (en) |
| WO (1) | WO1998039327A1 (en) |
| YU (1) | YU43499A (en) |
| ZA (1) | ZA981791B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704499D0 (en) * | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Method of manufacture |
| GB9825988D0 (en) * | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
| GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| CN110996948A (en) | 2017-06-12 | 2020-04-10 | 格莱泰施有限责任公司 | Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9321221D0 (en) * | 1993-10-14 | 1993-12-01 | Glaxo Spa | Heterocyclic compounds |
-
1997
- 1997-03-05 GB GBGB9704498.6A patent/GB9704498D0/en active Pending
-
1998
- 1998-03-03 KR KR1019997007987A patent/KR20000075907A/en not_active Application Discontinuation
- 1998-03-03 BR BR9808305-8A patent/BR9808305A/en not_active Application Discontinuation
- 1998-03-03 PE PE1998000149A patent/PE51399A1/en not_active Application Discontinuation
- 1998-03-03 YU YU43499A patent/YU43499A/en unknown
- 1998-03-03 ZA ZA9801791A patent/ZA981791B/en unknown
- 1998-03-03 HU HU0002109A patent/HUP0002109A2/en unknown
- 1998-03-03 EP EP98913613A patent/EP0966463A1/en not_active Withdrawn
- 1998-03-03 EA EA199900710A patent/EA199900710A1/en unknown
- 1998-03-03 CO CO98011404A patent/CO4940415A1/en unknown
- 1998-03-03 SK SK1196-99A patent/SK119699A3/en unknown
- 1998-03-03 AR ARP980100948A patent/AR011178A1/en unknown
- 1998-03-03 PL PL98335652A patent/PL335652A1/en unknown
- 1998-03-03 AU AU68251/98A patent/AU6825198A/en not_active Abandoned
- 1998-03-03 CN CN98803053A patent/CN1249750A/en active Pending
- 1998-03-03 JP JP53813598A patent/JP2001513796A/en active Pending
- 1998-03-03 ID IDW990976A patent/ID24207A/en unknown
- 1998-03-03 WO PCT/EP1998/001146 patent/WO1998039327A1/en not_active Application Discontinuation
- 1998-03-03 IL IL13148998A patent/IL131489A0/en unknown
- 1998-03-03 EE EEP199900387A patent/EE9900387A/en unknown
- 1998-03-03 CA CA002282851A patent/CA2282851A1/en not_active Abandoned
- 1998-03-03 NZ NZ337315A patent/NZ337315A/en unknown
- 1998-03-03 AP APAP/P/1999/001637A patent/AP9901637A0/en unknown
- 1998-03-03 TR TR1999/02117T patent/TR199902117T2/en unknown
- 1998-03-04 HR HR9704498.6A patent/HRP980114A2/en not_active Application Discontinuation
-
1999
- 1999-08-27 IS IS5166A patent/IS5166A/en unknown
- 1999-09-02 OA OA9900201A patent/OA11154A/en unknown
- 1999-09-03 NO NO994303A patent/NO994303L/en not_active Application Discontinuation
- 1999-10-04 BG BG103779A patent/BG103779A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK119699A3 (en) | 2000-05-16 |
| EP0966463A1 (en) | 1999-12-29 |
| AU6825198A (en) | 1998-09-22 |
| CO4940415A1 (en) | 2000-07-24 |
| PE51399A1 (en) | 1999-06-07 |
| IS5166A (en) | 1999-08-27 |
| NZ337315A (en) | 2001-02-23 |
| KR20000075907A (en) | 2000-12-26 |
| YU43499A (en) | 2000-12-28 |
| ID24207A (en) | 2000-07-13 |
| TR199902117T2 (en) | 2000-03-21 |
| BR9808305A (en) | 2000-05-16 |
| OA11154A (en) | 2003-04-16 |
| PL335652A1 (en) | 2000-05-08 |
| NO994303L (en) | 1999-11-03 |
| HRP980114A2 (en) | 1998-12-31 |
| ZA981791B (en) | 1999-09-03 |
| EE9900387A (en) | 2000-04-17 |
| BG103779A (en) | 2000-06-30 |
| CA2282851A1 (en) | 1998-09-11 |
| AP9901637A0 (en) | 1999-09-30 |
| GB9704498D0 (en) | 1997-04-23 |
| EA199900710A1 (en) | 2000-04-24 |
| WO1998039327A1 (en) | 1998-09-11 |
| NO994303D0 (en) | 1999-09-03 |
| HUP0002109A2 (en) | 2001-04-28 |
| JP2001513796A (en) | 2001-09-04 |
| CN1249750A (en) | 2000-04-05 |
| IL131489A0 (en) | 2001-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT915898E (en) | CLARITROMYCIN CRYSTALLINE I FORM | |
| BR9714082A (en) | Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound. | |
| BR9911482A (en) | Compound, pharmaceutical composition, use of the compound, and, processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound | |
| ATE201597T1 (en) | ADMINISTRATION OF RILUZOLE FOR THE TREATMENT OF NEURO-AIDS | |
| BR0212787A (en) | Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition | |
| ES2129485T3 (en) | DERIVATIVES OF GUANIDINOALKYL-1,1-BISPHOSPHONIC ACIDS, PROCEDURE FOR THEIR PREPARATION AND USE. | |
| AR019496A1 (en) | AZALIDAS OF 13 MEMBERS, PHARMACEUTICAL COMPOSITIONS, USE IN THE PREPARATION OF MEDICINES AND PREPARATION OF THE SAME | |
| ZA959451B (en) | 2,2-Dichloroalkanecarboxylic acids process of their production and pharmaceutical agents containing these | |
| BR9507381A (en) | Compound use of a compound process for the treatment of a manifest pharmaceutical composition and process for the preparation of compounds | |
| BR9611276A (en) | Compound pharmaceutical formulation process for treatment or prophylaxis of diseases or conditions of humans and use of a compound | |
| BR0011339A (en) | Compound, use, and process for preparing the same, pharmaceutical composition, and method for treating a metalloproteinase-mediated disease condition | |
| AR011178A1 (en) | SODIUM SALT COMPOUND OF (ACID (E) 4,6-DICHLORO-3- (2-OXO-1- FENILPIRROLIDIN-3-ILIDENO-METHYL) -1H-INDOL-2-CARBOXILICO IN ITS HYDRATED FORM, PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND METHOD OF TREATMENT USING SUCH COMPOUND | |
| ES2187534T3 (en) | PROCEDURE FOR THE PREPARATION OF N-METIL-3- (METIL-4-PIPERI DINIL) -14-INDOL-5-ETANOSULFONAMIDE. | |
| MX9400165A (en) | DERIVATIVES OF TER-BUTYLERGOLINE, PROCESS FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| AR002191A1 (en) | ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALCANOL COMPOUNDS IN THE FORM OF SOLUTION, PROCEDURE FOR ITS PREPARATION | |
| AR031126A1 (en) | AMINO ACIDS (OXO) INHIBITING ACETICS OF PROTEIN TIROSINA FOSFATASA | |
| AR008236A1 (en) | ANHYDRA CRYSTALLINE FORM OF R (-) - N- (4,4-DI (3- METHYLENE-2-IL) BUT-3-ENIL) -NIPECOTIC ACID, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH CRYSTALLINE SALT FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION | |
| ES2065855B1 (en) | PROCEDURE FOR THE PREPARATION OF NEW DEOXIAZAPHOSPHOLIPIDIC DERIVATIVES WITH INHIBITING ACTION OF THE PHOSFOLIPASE A2, NEW DERIVATIVES DEOXIAZAPHOSPHOLIPIDICES OBTAINED AND USE OF THEM. | |
| ES2170377T3 (en) | COMPOSITION CONTAINING QUITOSANA. | |
| BR0317425A (en) | Rabeprazole salt, the pharmaceutical composition containing it and the process for its preparation | |
| MX9704035A (en) | Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof. | |
| ZA824649B (en) | New optically active dipeptides, process for their preparation and pharmaceutical products containing these compounds | |
| MX9704036A (en) | 2-(2,3,5,6-tetrafluoro-4-pyridyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof. | |
| ES2158089T3 (en) | USE OF ALCALOID PHOSPHORATE DERIVATIVES FOR THE TREATMENT OF ENDOCRINOPATIAS. | |
| ES2062940A1 (en) | Gastrokinetic agent, process for its preparation and pharmaceutical compositions containing said agent |